AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 8612408
Drug: Dopamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dopamine infusion discontinued
Trial: 8612408
Drug: TRH administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH administration (200 micrograms, two consecutive doses)
Trial: 8612408
Drug: TRH administration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TRH administration (200 micrograms, two consecutive doses) after dopamine withdrawal
Trial: 2859861
Drug: Propranolol (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol (40 mg for 4 weeks)
Trial: 2859861
Drug: Metoprolol (low
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metoprolol (low dosage)
Trial: 2859861
Drug: Other beta-adrenoceptor
RxNorm normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other beta-adrenoceptor blockers (acebutolol, penbutolol, pindolol)
Trial: 30797394
Drug: Extended-release naltrexone
RxNorm normalized name: bupropion / naltrexone Extended Release Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Extended-release naltrexone (XR-NTX) implants
Trial: 26691247
Drug: DEC 300
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC 300 mg + Albendazole 400 mg sequential administration
Trial: 26691247
Drug: DEC 300
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC 300 mg + Albendazole 400 mg co-administration
Trial: 26691247
Drug: DEC 300
RxNorm normalized name: Zodryl DEC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DEC 300 mg + Doxycycline 100 mg co-administration
Trial: 26691247
Drug: Control regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control regimen DEC 300 mg
Trial: 22212494
Drug: 2% diltiazem
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2% diltiazem ointment
Trial: 15595331
Drug: Antiepileptic drugs
RxNorm normalized name: ANTIEPILEPTICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiepileptic drugs (AEDs) - phenobarbital, phenytoin, valproic acid
Trial: 12431962
Drug: High-dose therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose therapy (HDT) followed by involved-field radiotherapy (arm B)
Trial: 2007102
Drug: Lidocaine (0.7,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (0.7, 1.85, and 3.7 mg/kg) infused over 15, 45, and 75 minutes
Trial: 6180687
Drug: Ingestion of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ingestion of up to 300 mg of urushiol over three to six months
Trial: 2996444
Drug: Potassium citrate
RxNorm normalized name: Potassium Citrate
DrugBank: Potassium (DB14500)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Potassium citrate solution
Trial: 2996444
Drug: WHO oral
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: WHO oral rehydration solution
Trial: 28229572
Drug: CoQ10 supplementation
RxNorm normalized name: CoQ10
DrugBank: Ubidecarenone (DB09270)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: CoQ10 supplementation (200 mg per day for 4 weeks)
Trial: 28229572
Drug: Placebo (200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (200 mg per day for 4 weeks)
Trial: 23871132
Drug: Calcium phosphate
RxNorm normalized name: Calcium Phosphate
DrugBank: Calcium sulfate (DB15533)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium phosphate (1 g Ca as pentacalcium hydroxy-triphosphate)
Trial: 16167790
Drug: Clonidine 5
RxNorm normalized name: apraclonidine 5 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clonidine 5 microg x kg(‐1) and famotidine 20 mg
Trial: 16167790
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received oral famotidine alone
Trial: 12797394
Drug: Oral ofloxacin
RxNorm normalized name: Ofloxacin
DrugBank: Ofloxacin (DB01165)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oral ofloxacin prophylaxis (200 mg/2x12h)
Trial: 12797394
Drug: Control (standard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control (standard perioperative antibiotic prophylaxis with 2 g cefotiam)
Trial: 10782653
Drug: both agents
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: both agents
Trial: 21716127
Drug: Beclomethasone nasal
RxNorm normalized name: beclomethasone nasal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Beclomethasone nasal spray
Trial: 26812804
Drug: Active hypnotic
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active hypnotic drug
Trial: 22352703
Drug: Intravenous lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous lipid emulsion
Trial: 17095129
Drug: Menjugate vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menjugate vaccine stored at room temperature (25+/‐2 degrees C)
Trial: 17095129
Drug: Menjugate vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menjugate vaccine stored at 2‐8 degrees C
Trial: 9690722
Drug: Rennie (calcium‐magnesium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rennie (calcium‐magnesium carbonate) 1360 mg
Trial: 27977057
Drug: Otlertuzumab (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Otlertuzumab (20 mg/kg) weekly by IV infusion for two 28-day cycles then every 14 days for four 28-day cycles + IV bendamustine (70 mg/m2) on Days 1 and 2 of each cycle for up to six 28-day cycles
Trial: 26041316
Drug: Large dose
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large dose remifentanil (0.30 μg/kg/min) + low-dose naloxone (0.25 μg/kg/h)
Trial: 26041316
Drug: Small dose
RxNorm normalized name: smallpox vaccine live, New York City Board of Health vaccinia strain Injectable Solution [ACAM2000]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small dose remifentanil (0.1 μg/kg/min)
Trial: 26041316
Drug: Large dose
RxNorm normalized name: Largemouth bass
DrugBank: Largemouth bass (DB10976)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large dose remifentanil (0.30 μg/kg/min)
Trial: 23841967
Drug: Gesture Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gesture Therapy (virtual reality rehabilitation)
Trial: 11136169
Drug: Reference group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reference group (creatinine < 2.3 mg/dL)
Trial: 9264833
Drug: Immunotherapy with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immunotherapy with Transfer factor for three months
Trial: 3612828
Drug: Combination treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment format (communication skills followed by sexual skills)
Trial: 29489709
Drug: Cleansing solution
RxNorm normalized name: Cleansing Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cleansing solution and dressing material used before insertion and after removal of SPC.
Trial: 20851307
Drug: n-3 PUFA
RxNorm normalized name: 22:6(n-3)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: n-3 PUFA supplementation (1.7 g daily for 3 months)
Trial: 21966763
Drug: DHEA supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DHEA supplementation (50 mg/day for six months)
Trial: 2766869
Drug: Short-course ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Short-course ceftriaxone therapy (4, 6, and 7 days depending on the pathogen)
Trial: 2766869
Drug: Standard-length ceftriaxone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-length ceftriaxone therapy (twice as long as short-course)
Trial: 800972
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of muzolimine (80 mg) and spironolactone (300 mg)
Trial: 800972
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of furosemide (80 mg) and spironolactone (300 mg)
Trial: 800972
Drug: Placebo and
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo and spironolactone (300 mg)
Trial: 23539903
Drug: Ommaya reservoir
RxNorm normalized name: RESERVOIR,CADD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ommaya reservoir treatment
Trial: 23539903
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment methods
Trial: 19800704
Drug: Novel SIB
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Novel SIB strategy with prescribed mean doses of 46.8 Gy to PTV(risk), 50.6 Gy to PTV(pre_chemo), and 58.1 Gy to PTV(post_chemo) in 25 fractions.
Trial: 17074942
Drug: First acute
RxNorm normalized name: Cow first milk
DrugBank: Bos taurus colostrum (DB19249)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: First acute treatment step
Trial: 17074942
Drug: Second acute
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Second acute treatment step
Trial: 17074942
Drug: Third acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Third acute treatment step
Trial: 17074942
Drug: Fourth acute
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fourth acute treatment step
Trial: 11771024
Drug: Amitriptyline 50
RxNorm normalized name: amitriptyline 50 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitriptyline 50 mg/day for the first week and 100 mg/day for the following 5 weeks
Trial: 11771024
Drug: Placebo (lactose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (lactose starch tablets, 1 tablet/day for 6 weeks)
Trial: 7508219
Drug: LPS/NAME group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LPS/NAME group (NSR, LPS, and continuous infusion of 50 micrograms/kg per minute of N‐nitro‐L‐arginine methyl ester)
Trial: 27017701
Drug: Cytoflavin (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cytoflavin (10 mL in 200 mL of 0.9% sodium chloride for 10 days, then 2 tablets twice a day for 25 days)
Trial: 27017701
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment with oral antidiabetic drugs (metformin monotherapy or combined therapy)
Trial: 23170993
Drug: Therapy dog
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy dog visits (average duration 12 minutes)
Trial: 7878632
Drug: Fish oil
RxNorm normalized name: Fish oil
DrugBank: Fish oil (DB13961)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fish oil (6 g daily)
Trial: 27568006
Drug: Infant massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant massage therapy administered by the mother until term equivalent age (TEA)
Trial: 27568006
Drug: Infant massage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infant massage therapy
Trial: 23942774
Drug: Ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg + gp100 vaccine
Trial: 23942774
Drug: Ipilimumab 3
RxNorm normalized name: Ipilimumab
DrugBank: Ipilimumab (DB06186)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Ipilimumab 3 mg/kg + placebo
Trial: 23444228
Drug: gp100 vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: gp100 vaccine alone
Trial: 12707129
Drug: remifentanil 2
RxNorm normalized name: remifentanil 2 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil 2 micro g/kg
Trial: 12707129
Drug: remifentanil 3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil 3 micro g/kg
Trial: 12707129
Drug: remifentanil 4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: remifentanil 4 micro g/kg
Trial: 10972634
Drug: Naratriptan (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naratriptan (2.5 mg)
Trial: 11206864
Drug: Sumatriptan (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sumatriptan (100 mg)
Trial: 28540570
Drug: 250 mg
RxNorm normalized name: rutin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 250 mg magnesium oxide supplements daily for 12 weeks
Trial: 27207543
Drug: Vildagliptin (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vildagliptin (100 mg once daily for 10 days)
Trial: 27207543
Drug: Exendin [9-39]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exendin [9-39] (high-dose intravenous infusion)
Trial: 18468014
Drug: Midazolam 1
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 1 mg i.v. (Group M, n = 101)
Trial: 18468014
Drug: Midazolam 1
RxNorm normalized name: midazolam 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam 1 mg i.v. with fentanyl 25 microg (Group MF, n = 100)
Trial: 8897562
Drug: Prednisone, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone, 40 mg/m2 on alternate days for 12 months (control group)
Trial: 8897562
Drug: Prednisone, 40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone, 40 mg/m2 on alternate days for 12 months plus a 90‐day course of daily cyclophosphamide, 2.5 mg/kg in a single morning dose (experimental group)
Trial: 1510519
Drug: Automated closed-loop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Automated closed-loop titration system
Trial: 1510519
Drug: Manual nitroprusside
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual nitroprusside titration
Trial: 16336487
Drug: Medium dose
RxNorm normalized name: TRIGLYCERIDES,MEDIUM CHAIN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medium dose of a new uro-selective alpha-blocker
Trial: 16336487
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose of a new uro-selective alpha-blocker
Trial: 16336487
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose of a new uro-selective alpha-blocker
Trial: 12386911
Drug: SCOFF administered
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SCOFF administered orally
Trial: 12386911
Drug: SCOFF administered
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SCOFF administered in written format
Trial: 12386911
Drug: SCOFF administered
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: SCOFF administered verbally first
Trial: 8576893
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy including a diuretic
Trial: 8576893
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy without a diuretic
Trial: 8576893
Drug: Single drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single drug treatment (hydrochlorothiazide, atenolol, captopril, clonidine, diltiazem-SR, prazosin)
Trial: 19801363
Drug: GLP-1 receptor
RxNorm normalized name: GLP-1 receptor agonist
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 receptor agonists (exenatide, liraglutide)
Trial: 19801363
Drug: DPP-4 inhibitors
RxNorm normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: DPP-4 inhibitors (sitagliptin, alogliptin, saxagliptin)
Trial: 19801363
Drug: Monotherapy (diet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (diet and exercise)
Trial: 19801363
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (oral antihyperglycemic regimens)
Trial: 12032025
Drug: Ondansetron continuous
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron continuous infusion (1 mg. mL(‐1). h(‐1))
Trial: 9442775
Drug: External beam
RxNorm normalized name: Beam
DrugBank: Tricyclazole (DB02891)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: External beam radiation therapy (5 fractions of 200 cGy 6 MV external beam photons)
Trial: 7633300
Drug: Methadone maintenance
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone maintenance treatment at Clinic 2 (long-term maintenance)
Trial: 7633300
Drug: Time-limited treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Time-limited treatment aimed at abstinence at Clinic 1
Trial: 7633300
Drug: Methadone dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methadone dose of 80 mg/day
Trial: 7633300
Drug: Average doses
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Average doses prescribed in Clinic 1 (lower doses)
Trial: 2520344
Drug: Inhaled frusemide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled frusemide (approximately 28 mg delivered into the mouth)
Trial: 238278
Drug: Trimepranol (15
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Trimepranol (15 mg daily for 16 weeks)
Trial: 29681434
Drug: Ruxolitinib 15
RxNorm normalized name: ruxolitinib 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ruxolitinib 15 mg b.i.d. plus pemetrexed (500 mg/m2 intravenous, day 1) and cisplatin (75 mg/m2 intravenous, day 1)
Trial: 29681434
Drug: Placebo plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo plus pemetrexed (500 mg/m2 intravenous, day 1) and cisplatin (75 mg/m2 intravenous, day 1)
Trial: 28886745
Drug: Active drug
RxNorm normalized name: Capillary active drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active drug (optimal dose)
Trial: 26259064
Drug: Traditional Chinese
RxNorm normalized name: BORNEOL 1 g in 6.5 g / MINT 1 g in 6.5 g / ANGELICA DAHURICA ROOT 0.5 g in 6.5 g TOPICAL POWDER [Traditional Chinese Medicine Health Card and TCM Epidemic Prevention Card]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Traditional Chinese Medicine (TCM) drugs
Trial: 8704804
Drug: Methotrexate (MTX)
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Methotrexate (MTX) 1 mg/kg injected transvaginally or 1.5 mg/kg IM if necessary (group 1)
Trial: 6666698
Drug: Daily calorie
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily calorie referencing with no further calorie goals
Trial: 30767504
Drug: Supplemental oxygen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Supplemental oxygen at 6 L/min for 6 to 12 hours delivered by open face mask
Trial: 20622335
Drug: Compound Polygonum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Compound Polygonum multiflorum extract
Trial: 20622335
Drug: Naofukang (western
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naofukang (western medicine control)
Trial: 12354084
Drug: Mechanical treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mechanical treatment using curettes
Trial: 10407818
Drug: Doxapram (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxapram (0.5 mg/kg/h continuous infusion)
Trial: 10407818
Drug: Theophylline (loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theophylline (loading dose 5 mg/kg, 3 mg/kg bid)
Trial: 2075080
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of both agents (Cefuroxime + Metronidazole)
Trial: 28597604
Drug: Lesinurad 400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad 400 mg
Trial: 27826183
Drug: Lesinurad 1,600
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lesinurad 1,600 mg (supratherapeutic dose)
Trial: 22528707
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (AADs) - metoprolol, propafenone, verapamil
Trial: 22528707
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (AADs) - responders
Trial: 22528707
Drug: Antiarrhythmic drugs
RxNorm normalized name: ANTIARRHYTHMICS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic drugs (AADs) - long-term follow-up
Trial: 20233135
Drug: Deferred invasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred invasive treatment (balloon angioplasty or coronary bypass surgery)
Trial: 20233135
Drug: Deferred invasive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Deferred invasive treatment
Trial: 9797801
Drug: Sampatrilat (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sampatrilat (50 mg, 100 mg, 200 mg)
Trial: 2624612
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nifedipine (generic preparation P)
Trial: 2624612
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg nifedipine (reference preparation R)
Trial: 30647445
Drug: Loading dose
RxNorm normalized name: NUZYRA 7-Day Oral Pack including loading dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Loading dose guided by pharmacogenetics (LDG)
Trial: 30647445
Drug: Maintenance dose
RxNorm normalized name: Firmagon 80mg Powder for Injection Maintenance Dose Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maintenance dose (MDG)
Trial: 26098993
Drug: Baseline HCV
RxNorm normalized name: HCV-086
DrugBank: HCV-086 (DB05884)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baseline HCV RNA <400,000 IU/mL